Tracking Francis Chou’s Chou Associates Portfolio – Q2 2017 Update

• Chou’s 13F portfolio increased from $301M to $324M during the quarter.
•  Chou increased Valeant and Teva Pharmaceuticals.
• Valeant at ~16% of the portfolio is the largest position.

Francis Chou’s Chou Associates Portfolio increased 7.42% from $301M to $324M during the quarter. The portfolio continues to be very concentrated with just 27 positions. Below is a summary:

1. Berkshire Hathaway (BRK.A): The ~12% portfolio position is the second-largest 13F equity stake. The last major activity was a 50% reduction in Q1 2016 at prices between $187,000 and $214,000. The stock is now at $270,420.  

2. JPMorgan Chase Warrants (JPM-WT): The 9.76% stake in JPMorgan TARP Warrants was acquired in 2011 at much lower prices. The position had remained relatively steady since. Last quarter saw a ~44% selling as the underlying traded between $83 and $94. JPM currently goes for $91.31.

3. Resolute Forest Products (RFP): The ~7% RFP position has been in the portfolio since 2010 (Abitibibowater at the time) and the cost-basis is much higher compared to the current price. Q2 2013 saw a one-third increase at prices between $13 and $16. The five quarters through Q1 2016 also saw a ~20% combined increase at progressively lower prices between $4 and $19. The stock is now at $4.90.

4. Valeant Pharmaceuticals (VRX): VRX is now the largest position at 16.38% of the portfolio. The position was established in Q1 2016 at prices between $26 and $102 and increased by ~48% the following quarter at prices between $19 and $36. There was another ~35% increase in Q4 2016 at prices between $13.50 and $24.50 and that was followed with a ~20% increase last quarter at prices between $10.50 and $17. This quarter saw another ~30% increase at prices between $8.50 and $17.30. The stock currently trades at $13.19.

Below is a spreadsheet that highlights the changes to the portfolio as of Q2 2017. Please check out our previous update to have an idea on how the portfolio is progressing:

To learn more about how to profit from a strategy of cloning hedge fund picks, check out our book Profiting from Hedge Funds: Winning Strategies for the Little Guy .